News Archive Take a trip down Theragnostics memory lane with our news archive below Theragnostics strengthens leadership team with two key appointmentsNovember 13, 2019GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019Theragnostics Reports Positive Clinical Trial Results from Prostate Cancer StudyOctober 2, 2019Theragnostics will be @ EANM ’19 – Booth #4September 30, 2019THERAGNOSTICS SIGNS AGREEMENT WITH ASTRAZENECASeptember 5, 2019Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals SummitJune 12, 2019Is it June already?! – Meet us @ SNMMI ’19June 6, 2019Theragnostics Ltd Expands Oncology Portfolio with Licensing of radioPARP InhibitorFebruary 28, 2019Theragnostics will be at the Theranostics World Congress 2019February 20, 2019We are hiring! – Chief Medical Officer (application window now closed)February 19, 2019Nick Stevens appointed Executive Chairman Theragnostics LtdJanuary 25, 2019Theragnostics will be at EANM ’18September 10, 2018Theragnostics Announces Partnership with ROTOP and Establishes U.S. HeadquartersAugust 23, 2017We’ve launched our new website!March 31, 2017Theragnostics partners with PCCA for UK distributionJuly 30, 2018First patient enrolled in our Phase II prospective study of 68Ga-THP-PSMAJune 25, 2018Theragnostics will be in Philly for SNMMI 2018May 25, 2018New Study Demonstrates Safety And Biodistribution Of An Easy Use One-Step Radiopharmaceutical Kit For Prostate Cancer ImagingOctober 9, 2017Theragnostics strengthens leadership team with two key appointmentsNovember 13, 2019GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019Theragnostics Reports Positive Clinical Trial Results from Prostate Cancer StudyOctober 2, 2019Theragnostics will be @ EANM ’19 – Booth #4September 30, 2019THERAGNOSTICS SIGNS AGREEMENT WITH ASTRAZENECASeptember 5, 2019Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals SummitJune 12, 2019Is it June already?! – Meet us @ SNMMI ’19June 6, 2019Theragnostics Ltd Expands Oncology Portfolio with Licensing of radioPARP InhibitorFebruary 28, 2019Theragnostics strengthens leadership team with two key appointmentsNovember 13, 2019GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019Theragnostics Reports Positive Clinical Trial Results from Prostate Cancer StudyOctober 2, 2019Theragnostics will be @ EANM ’19 – Booth #4September 30, 2019THERAGNOSTICS SIGNS AGREEMENT WITH ASTRAZENECASeptember 5, 2019Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals SummitJune 12, 2019Is it June already?! – Meet us @ SNMMI ’19June 6, 2019Theragnostics Ltd Expands Oncology Portfolio with Licensing of radioPARP InhibitorFebruary 28, 2019
GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019
New Study Demonstrates Safety And Biodistribution Of An Easy Use One-Step Radiopharmaceutical Kit For Prostate Cancer ImagingOctober 9, 2017
GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019
GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019
